Seres Therapeutics, Inc.
MCRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001609809
In the last 90 days, Seres Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $17.9M in total; no superinvestor holds it.
Holders of 5% or more of MCRB
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Seres Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Seres Therapeutics, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
35 Schedule 13D and 13G filings on Seres Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 6, 202512:23 PM ET | FMR LLCand 1 other | 13G/A | 3.10%268.7K shares | −2.60 ppfrom 5.70%Below 5% | Jun 30, 2025 | SEC |
| Jun 6, 202510:03 AM ET | FMR LLCand 1 other | 13G/A | 5.70%493.6K shares | −7.10 ppfrom 12.80% | May 30, 2025 | SEC |
| Feb 12, 20259:22 AM ET | FMR LLCand 1 other | 13G/A | 12.80%21.8M shares | – | Dec 31, 2024 | SEC |
| Feb 12, 2024 | Janus Henderson Group PLC | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2024 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Jan 29, 20245:25 PM ET | BlackRock Inc. | 13GOld format | – | – | – | SEC |
| Nov 7, 202312:57 PM ET | Federated Hermes, Inc. | 13G/AOld format | – | – | – | SEC |
| May 10, 202310:16 AM ET | Federated Hermes, Inc. | 13G/AOld format | – | – | – | SEC |
| Apr 6, 20239:29 AM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2023 | Janus Henderson Group PLC | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2023 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2023 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 3, 202312:10 PM ET | BlackRock Inc. | 13GOld format | – | – | – | SEC |
| Feb 3, 2023 | State Street Corp | 13G/AOld format | – | – | – | SEC |
| Feb 1, 202312:15 PM ET | Federated Hermes, Inc. | 13G/AOld format | – | – | – | SEC |
| Aug 9, 20224:02 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Jul 22, 2022 | Nestle Health Science US Holdings, Inc. | 13D/AOld format | – | – | – | SEC |
| Jul 11, 20222:13 PM ET | Federated Hermes, Inc. | 13G/AOld format | – | – | – | SEC |
| Jul 7, 2022 | Flagship VentureLabs IV, LLC | 13D/AOld format | – | – | – | SEC |
| Feb 14, 20221:46 PM ET | Federated Hermes, Inc. | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | Nikko Asset Management Americas, Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Ra Capital Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Janus Henderson Group PLC | 13GOld format | – | New | – | SEC |
| Feb 10, 2022 | Vanguard Group Inc | 13GOld format | – | New | – | SEC |
| Feb 9, 2022 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 4, 2022 | Sumitomo Mitsui Trust Holdings, Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 3, 20224:41 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Jan 10, 2022 | State Street Corp | 13G/AOld format | – | – | – | SEC |
| Oct 12, 2021 | State Street Corp | 13GOld format | – | New | – | SEC |
| May 5, 2021 | Ra Capital Management, L.P. | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | ARK Investment Management LLCSuperinvestorARK Invest | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2021 | Nikko Asset Management Americas, Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 8, 2021 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 5, 2021 | Sumitomo Mitsui Trust Holdings, Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 1, 20218:30 AM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Seres Therapeutics, Inc. shares.
No Form 144 notices for Seres Therapeutics, Inc. are on file.